Saegis Pharmaceuticals
Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
$30.0m | Series B | ||
| Total Funding | 000k | ||
Related Content
Saegis Pharmaceuticals was a company that focused on developing and commercializing medicines for disorders of the brain and central nervous system. The company's main focus was on neurological conditions that affect memory and cognition.
Saegis was building a portfolio of small molecule therapeutic compounds. These were aimed at treating conditions such as Alzheimer's disease, mild cognitive impairment, and adult attention deficit disorder. The company's strategy involved a combination of in-licensing promising compounds and conducting its own research and development to bring these potential therapies to market.
Founded in 1999 and based in California, Saegis Pharmaceuticals operated in the biotechnology and pharmaceutical sector. In November 2008, the company was acquired by Lundbeck, a global pharmaceutical company. This acquisition marked the conclusion of Saegis's operations as an independent entity.
Keywords: small molecule therapeutics, neurological disorders, central nervous system, Alzheimer's disease, cognitive decline, memory loss, pharmaceuticals, biotechnology, clinical trials, in-licensing